BioSpace News Archive

HIL Applied Medical, a global leader in developing a new class of Proton Therapy systems, together with its partner Proton International (P.I.), announced today that the companies have been awarded a $900K grant from the Israel-U.S. Binational Industrial Research and Development (BIRD) Foundation.

Intrinsic Therapeutics, Inc., a medical device company focused on preventing reherniation and reoperation following lumbar discectomy, today announced the publication in JAMA Network Open of the five-year follow-up results from its landmark clinical trial demonstrating that the use of Barricaid following discectomy is superior to treating high-risk patients with discectomy alone.

Atomwise, a leader in using artificial intelligence (AI) for small molecule drug discovery, announced today the appointment of David Thomson, Ph.D. as Chief Scientific Officer.

Menten AI partners with Xanadu to build solutions on top of Xanadu’s open-source software, PennyLane, to design novel drug molecules that can efficiently bind to a specific target of interest.

ObjectiveHealth, the integrated research and digital health services company, announced today that they have attained the necessary scale to validate digital health models and optimize clinical research activities.

Iterative Scopes,announced today that it has entered into a collaboration with Janssen Research & Development, LLC (Janssen) in which Iterative Scopes will work with the Janssen Data Science and Immunology teams to augment Janssen’s clinical trials for inflammatory bowel disease (IBD) with the deployment of cutting-edge artificial intelligence (AI) and computer vision tools.

Calysta, Inc. World-leading alternative protein producer, Calysta, has signaled its future intentions with the appointment of Dr Lori Giver, as Chief Science and Sustainability Officer.

Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announces that HonorHealth has established a robotic electrophysiology program as part of its Cardiovascular Center of Excellence at HonorHealth Scottsdale Shea Medical Center in Scottsdale, Arizona.

SNIPR BIOME ApS, a leading CRISPR and microbiome biotechnology company, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for SNIPR001.

Excellos, Incorporated, a cell therapy Contract Development and Manufacturing Organization, announces its official corporate launch and closing of $15M in growth funding from Telegraph Hill Partners.